For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025
Summarize this article with:
This section is Partnership Content suppliedThe content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentFerring’s total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur®Continued ramp-up in the US for Adstiladrin®, our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driverCommitment to sustainability demonstrated by SBTi approval of our targets to reduce greenhouse gas emissions, and by our programme to reduce maternal deaths in low- and lower middle-income countriesSign In or Create an AccountEmail AddressContinueor View more offersArticle contentArticle contentSAINT-PREX, Switzerland — Ferring today published its 2025 Annual Report and Sustainability Report. The company achieved total revenues of over €2.5 billion in 2025, an increase of 7% over the previous year at actual exchange rates (AER) and 10% at constant exchange rates (CER). These were mainly driven by our flagship product Menopur® (menotropins for injection) in reproductive medicine, and the ramp-up in the US of our breakthrough gene-based therapy for non-muscle invasive bladder cancer, Adstiladrin® (nadofaragene firadenovec-vncg).Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentOperating expenses were contained to an increase of €61 million year-on-year (i.e. +5% at AER and +7% at CER), and this includes significant non-recurring items (notably impairment charges and restructuring provisions). Underlying operating expenses remained well-controlled, with increased investments targeted to support the growth of Adstiladrin and other opportunities. Thus, operating profit for the year reached €167 million, a decrease of -€24 million (‑13%) versus the prior year at AER, while remaining flat at CER – with the difference being driven by the weaker US dollar.Article contentFollowing a focus on improving cash conversion after several heavy investments, free cash flow generation approached neutral despite currency headwinds from the weaker US dollar. This represents a substantial improvement compared to the previous year, and a significant step towards sustainable cash generation.Article contentJean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer, said: “This was a pivotal year as we continued evolving our business to become stronger, more agile and more resilient, and importantly we got back to free cash flow neutral. Moreover, in 2025, we introduced an enterprise model designed to create greater value for patients and customers while supporting sustainable growth. This reflects our long-term commitment to serving patients’ need, and fostering an environment where people can learn, grow and perform at their best.” Ferring has always conducted business responsibly by seeking to protect the environment, create value for society, and uphold our high standards of ethics and governance. In 2025, we passed a major milestone when our targets for reducing greenhouse gas (GHG) emissions were approved by the Science Based Targets initiative (SBTi). This globally recognised standard ensures corporate goals are aligned with international climate policy. During the year, we succeeded in reducing our Scope 1 and 2 GHG emissions by 4.3% and Scope 3 emissions by 19%.Article contentArticle contentAccess to affordable healthcare is embedded in Ferring’s purpose and strategic priorities.
The Project Family™: Safe Birth initiative aims to reduce maternal deaths in low- and lower middle-income countries by enabling wider access to Carbetocin Ferring (carbetocin, room-temperature stable formulation). In 2025, we worked with partners to supply around 1.7 million doses of this life-saving medicine at an affordable access price, while gaining further approvals in seven low- and lower middle-income countries.Article contentAbout Ferring PharmaceuticalsArticle contentFerring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.Article contentLearn more at www.ferring.com, or connect with us on LinkedIn, Instagram and YouTube.Article contentArticle contentArticle contentArticle contentView source version on businesswire.com: Article content https://www.businesswire.com/news/home/20260310378948/en/Article contentArticle contentContactsArticle contentFor more information, please contactArticle contentCarine Julen Article contentArticle contentSenior Manager, Corporate Communications & Public Affairs Article contentArticle contentcarine.julen@ferring.comArticle content#distroArticle contentTrending Here's why bets are rising for interest rate hikes including for Canada Economy Subscriber only. It's been five years since mortgage rates hit all-time lows, and no one is celebrating this anniversary Subscriber only Personal Finance Qatar to push LNG expansion plans to 2027 after Iran drone attack Oil & Gas Vietnam Plans to Scrap Fuel Import Curbs to Keep Supply Flowing PMN Business Posthaste: How $100 oil could do Canada's economy more harm than good News Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Here's why bets are rising for interest rate hikes including for Canada Economy Subscriber only. It's been five years since mortgage rates hit all-time lows, and no one is celebrating this anniversary Subscriber only Personal Finance Qatar to push LNG expansion plans to 2027 after Iran drone attack Oil & Gas Vietnam Plans to Scrap Fuel Import Curbs to Keep Supply Flowing PMN Business Posthaste: How $100 oil could do Canada's economy more harm than good News